CD34 and HIV infectious disease: Potential shortcomings of the present modelling relate to the additional effect of gene therapy on cell populations other than CD4+T cells, given that G+ CD34+ HSC also differentiate into macrophages and monocytes that are susceptible to HIV infection [3], [5].